Skip to main content

Logo
  • Live News iconLive News
  • Smart Screener iconSmart Screener
  • Trade Opportunities iconTrade Opportunities
  • Alpha Watch iconAlpha Watch
  • Catalyst iconCatalyst
Skip to main content
Stock Ask Logo
Hi, Guest User

Log in or create an account to get full access

Open an Account (opens in a new window)

TOOLS

Live News
Smart Screener
Trade Opportunities
Alpha Watch
Catalyst

StockkASK powered by Indira Securities

Windlas Biotech Ltd (WINDLAS) Share Price & Fundamentals

SegmentOfferingsAdvantages / MoatCustomersHigh-Margin AreasRevenue (₹ Cr.)Revenue %How We EarnPricing ModelGrowth DriversTop Brands
Generic Formulations CDMOEnd-to-end formulation development, licensing and manufacturing services including injectables and complex formatsProprietary IP on 99% products, WHO-GMP facilities, experienced R&D and regulatory teams, strong client relationshipsPrimarily B2B pharma companies in India and select export marketsComplex formulations, modified-release and injectable products55573Contract manufacturing revenues from domestic and international pharmaceutical companiesContractual pricing; regulated by supply agreements and product development milestonesLaunch of complex generics, capacity expansion, increased client base and regulatory approvals~5582 products supplied to 757 clients; specialized in chronic & complex generics
Trade Generics & InstitutionalBranded generic drugs sold to stockists, distributors, and institutional buyers like government schemesStrong brand portfolio, wide distributor network, understanding of institutional procurementStockists, distributors, government institutions; B2B and B2GBranded generics in chronic segments with direct market reach40023Sales revenue from brand-owned generics distributed through trade and tender salesDirect sales; competitive pricing aligned with institutional procurementRural market penetration, government healthcare schemes, expanding branded generic portfolio400+ generic brands sold domestically including institutional tenders
ExportsGeneric pharmaceutical products including formulations and health supplements for emerging and semi-regulated marketsRegulatory dossiers, WHO-GMP certification, and export infrastructureInternational pharmaceutical distributors and partners; B2BComplex generics in priority export markets274Sale of branded and unbranded generics through export contractsContractual and order based sales with compliance to recipient country regulationsGeographic expansion, dossier registration, and product portfolio diversificationExport of ~80 generic medicines to 10 countries

StockkASK provides smart, AI-powered insights to support analysis. AI can make mistakes; verify independently before investing.Terms & Conditions